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Background: Radiation therapy (RT) is the current gold standard for palliation of painful 
vertebral metastases. However, other percutaneous modalities such as radiofrequency ablation 
(RFA), cryoablation, and vertebral augmentation have also been shown to be effective in alleviating 
symptoms. Combined RT and ablation may be more effective than either therapy alone in palliating 
painful metastatic disease to the spine.
Objective: To evaluate the safety and efficacy of combined ablation, either RFA or cryoablation, 
and RT in the treatment of spinal metastases. 
Study Design: Retrospective study.
Setting: This is a retrospective study at a single institution.
Methods: Medical records of all patients who underwent ablation of spine lesions at a single 
institution between March 2012 and June 2014 were reviewed; patients treated with both RT 
and either RFA or cryoablation concurrently were identified. Pain scores before and after RFA were 
measured with the numerical rating scale (NRS) (0 – 10 point scale) and compared. Procedural 
complications, changes in general activity level, and pain medication usage after ablation were also 
recorded. When available, follow-up imaging was evaluated for evidence of residual or recurrent 
disease.
Results: Twenty-one patients with 36 spine metastases were treated with RT and percutaneous 
ablation concurrently; either RFA (21/22) or cryoablation (1/22). One patient received 2 separate 
RFA treatments. Overall, mean worst pain score (8.0, SD = 2.3) significantly decreased at both 
one week (4.3, SD = 3.1; P < .02) and 4 weeks (2.9, SD = 3.3; P < .0003). Temporary post-
procedural radicular pain occurred after one RFA treatment (4.5%; 1/22). Seven patients had 
radiation resistant tumors (renal cell, melanoma, or sarcoma). Post-procedural imaging (median 
6 months; range 2 – 27 months) showed stable treated disease in 12/13 treatments at 3 months 
and 10/10 at 6 months. 
Limitations: The therapeutic effect of vertebral augmentation versus percutaneous ablation 
cannot be separated in this retrospective study. Radiation treatment protocols were variable and 
included both stereotactic body and conventional RT which may have different safety and efficacy 
profiles.
Conclusion: Percutaneous ablation and concurrent RT is safe and effective in palliating painful 
spinal metastases and can be effective in those who have radiation resistant tumor histology. 
Key words: Interventional spine oncology, pain, percuataneous ablation, radiofrequency 
ablation, cryoablation, radiation therapy, spine metastases, vertebroplasty
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Portability and Accountability Act compliant. Consent 
was waived for retrospective study participation. Medi-
cal records of all patients who underwent percutane-
ous ablation of bone lesions at our institution between 
March 2012 and June 2014 were reviewed. Patients with 
spinal metastases treated concurrently with either RFA 
or cryoablation and conventional or stereotactic body 
radiation therapy (SBRT) were identified. Concurrent 
treatment was defined as less than 4 weeks between 
RT and ablation. Prior to undergoing percutaneous 
ablation, patients were discussed in a multidisciplinary 
spinal tumor board conference including radiation 
oncology, radiology, orthopedic spine surgery, and 
neurosurgery. 
On the day of the ablation procedure, pre-proce-
dural worst pain in 24 hours was measured with the nu-
merical rating scale (NRS) (0 – 10 point scale). Analgesic 
use histories were also recorded by the nurse coordina-
tor. Subsequent pain scores and changes in general ac-
tivity and analgesic medication use were then obtained 
via telephone interview one week and one month 
after the procedure by the nurse coordinator. Analge-
sic medication use was defined as more, same, or less 
absolute mg/day. General activity was categorized as 
more, same, or less compared to pre-procedural levels. 
When multiple contiguous spinal levels were treated in 
a single ablation procedure, pain scores were applied to 
the entire procedure as a single treatment, as it is not 
typically possible to discern which individual lesion is 
contributing to a patient’s pain. Chart reviews were also 
performed for evidence of complications. As this was a 
retrospective study, a post-ablation imaging protocol 
was not established and imaging ordering was primar-
ily directed by the treating oncologist to monitor over-
all disease status. When available, the post-treatment 
imaging was evaluated by musculoskeletal radiologists 
and neuroradiologists for evidence of residual or recur-
rent tumor at the treated levels.
Procedure Methods
Pre-procedural planning was performed using 
cross-sectional imaging to determine pedicle access and 
the expected number of targeted ablations. Magnetic 
resonance imaging (MRI) was preferred due to better 
evaluation of the extent of vertebral body and pedicle 
involvement, as well as tumor extension into the cen-
tral canal and/or neural foramen. 
Prior to the procedure, written informed consent 
was obtained. Conscious sedation with fentanyl and 
midazolam was used in all cases, and no cases required 
The most common site of osseous metastases is the spine, which accounts for 40% of all osseous metastatic disease. Pain associated with these 
metastases has a significant impact on patients’ quality 
of life (1-6). Treatment of spinal metastases is usually 
palliative with goals of therapy including timely control 
of pain, local tumor control to prevent neurological 
deficits, and mechanical stabilization to preserve 
function (1). Therefore, historic treatment has been 
mostly noninvasive, utilizing analgesics, chemotherapy, 
and radiotherapy. Surgery is traditionally only considered 
for oligometastatic or radiation resistant tumors (e.g., 
sarcoma, melanoma, and renal cell), spinal instability, 
symptomatic neural compression, or intractable pain 
unresponsive to non-operative measures (1).
For patients with localized pain due to spinal me-
tastases that is uncontrolled with analgesics, systemic 
chemotherapy, and/or bone-seeking radionuclides, 
conventional external beam radiation therapy (cEBRT) 
is the standard of care (7). However, radiation therapy 
(RT) has several important clinical limitations that em-
phasize the need for adjunctive or alternative thera-
peutic modalities. First, many patients’ response to RT 
is unsatisfactory with partial and complete palliation 
rates of 48 – 50% and 15 – 18%, respectively (8-10). 
Second, patients often develop recurrent pain, and 
retreatment with RT is only effective for 40% of these 
patients (9,10). Third, patients may not experience pain 
relief for several weeks (9,10). Finally, once normal tis-
sue dose limits have been reached, recurrent pain at 
a previously irradiated site or adjacent vertebral level 
often cannot be re-treated with additional RT. 
Recent studies have demonstrated image-guided 
minimally invasive techniques of radiofrequency abla-
tion (RFA), cryoablation, and vertebral augmentation 
to be safe and effective in treating symptomatic meta-
static osseous disease (11-15). Percutaneous ablation 
with cement stabilization not only rapidly relieves pain 
(often immediately post procedure) but it does not re-
quire interruption of other systemic therapies (12-14). 
Some authors have postulated that combined RT and 
RFA may function synergistically to achieve better out-
comes compared with RT or RFA alone (15). This study 
evaluates the safety and efficacy of combined percu-
taneous ablation and RT in the treatment of spinal 
metastases at a single institution. 
Methods
This retrospective study was approved by our 
institutional review board and was Health Insurance 
www.painphysicianjournal.com  575
Combined Ablation and Radiation Therapy of Spinal Metastases
general anesthesia. Local and periosteal anesthesia 
was achieved with a combination of 1% lidocaine and 
0.25% bupivacaine. Fluoroscopy was used for imaging 
guidance for all of the RFA treatments, and computed 
tomography (CT) was used for the cryoablation treat-
ment. The vertebral bodies were accessed via a transpe-
dicular approach using a 10-gauge introducer working 
cannula. A bipedicular approach was used when the 
tumor involved more than 50% of the posterior wall. 
RFA was performed by using the STAR Tumor Abla-
tion System (DFINE, San Jose, Calif), consisting of the 
Spine STAR ablation instrument and the MetaSTAR gen-
erator. The number of performed ablations was deter-
mined by the tumor size and location on cross-sectional 
imaging in conjunction with real-time thermocouple 
temperature readings that correspond to the volume 
of each individual ablation zone. The ellipsoid ablation 
zone in relation to thermocouple temperatures is based 
on manufacturer thermal distribution curves with maxi-
mum dimensions of 30 mm long by 20 mm wide when 
the proximal thermocouple reaches 50°C and 20 mm × 
13 mm when the distal thermocouple is 50°C (16). Op-
timal tissue destruction occurs between 50 – 90°C (17). 
The mean cumulative ablation time per lesion was 9:45 
minutes (range 2:30 – 24:13 minutes). To ensure abla-
tion of most of the tumor at the treated level, multiple 
ablation zones were used with a mean of 8 overlapping 
ablation zones per treated level. The tumors ranged in 
size from 1.6 cm maximum diameter to involving the 
entire vertebral body with paraspinal extension. The 
mean temperature recorded at the proximal thermo-
couple on the electrode (representing the temperature 
reading at the most peripheral aspect of the ablation 
zone) was 50.9°C, and the mean temperature recorded 
at the distal thermocouple was 74.9°C. 
Cryoablation was performed with Galil (Galil Medi-
cal, Yokneam, Israel) cryoprobes. Cryoablation was per-
formed with a 10 minute freeze cycle followed by a 7 
minute active thaw and then another 10 minute freeze 
cycle. CT images were obtained at both the 5 minute 
and 10 minute intervals. Neuroforaminal thermal moni-
toring was performed in the cryoablation case. Neural 
thermal protection involved neuroforaminal injection of 
CO2 (18-20). This was performed by placing an 18-gauge 
spinal needle in the region of the neuroforamen with 
placement of a thermocouple coaxially into the neuro-
foramen to measure temperatures. The thermal couple 
temperatures never went below 10°C (18-20). 
After ablation, cement augmentation (StabiliT 
Vertebral Augmentation System; DFINE, San Jose, CA) 
was performed (35/36 lesions) via the same working 
cannula. The osteoblastic metastasis treated with cryo-
ablation did not receive cement. Five (5/22) treatments 
were supplemented by central epidurals or selective 
nerve root blocks because of pre-existing radicular pain 
or pedicle involvement by tumor.
Statistical Methods
A paired unequal variance 2-tailed Student t test 
was used to compare pain scores before ablation with 
pain scores one week and one month after ablation; 
assuming a hypothetical mean difference of 2, P-values 
< 0.05 were considered statistically significant (21,22). 
Treatment responses were categorized categorically 
with partial pain relief defined as ≥ 2 point pain score 
reduction and complete relief defined as post-proce-
dural pain score ≤ 1 (7,23).
results
Twenty-one patients with 36 spine metastases 
were treated with percutaneous ablation, either RFA or 
cryoablation, and RT to the same level between March 
2012 and June 2014. One patient received 2 separate 
RFA treatments for a total of 21 RFA and one cryoab-
lation procedures. This subgroup analysis includes 9 
patients who were included in a previously reported 
cohort of 73 patients (119 lesions) that had vertebral 
RFA ablation (14). However, analysis of the effect of 
concurrent radiation was not evaluated in that prior 
study. There were 13 men (59%) and 9 women (41%). 
The mean patient age was 61.8 years (range, 30 – 84 
years). The most common types of primary tumor were 
non-small cell lung cancer (38%, 8/21) and renal cell 
carcinoma (24%, 5/21). Other tumors included breast 
cancer (14%, 3/21), rectal cancer (9%, 2/21), and single 
cases of bladder, angiosarcoma, and melanoma. Seven 
patients had tumors that are traditionally considered 
radiation resistant (renal cell, melanoma, or sarcoma). 
Of the vertebral bodies treated, 42% (15/36) were tho-
racic and 58% (21/36) were lumbar. 
The radiation therapy treatments were variable 
depending on the institution and provider. The major-
ity of patients received 30 Gy in 10 fractions (12/22). 
Other treatment regimens included stereotactic body 
radiation therapy (SBRT) (6/22), 20 Gy in 5 fractions 
(1/22), and 8 Gy in a single fraction (1/22). Two treat-
ment regimens were unknown. 
Twenty-one RFA treatments and one cyroabla-
tion were performed in combination with RT. The 
pre-procedural mean worst pain score (8.0, SD = 2.3) 
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significantly decreased at both one week (4.3, 
SD = 3.1; P < .02) and 4 weeks (2.9, SD = 3.3; 
P < .0003) following ablation treatments. The 
mean worst pain decreased by 3.8 (95% CI 2.3 
– 5.4) at one week and 5.1 (95% CI 3.3 – 6.9) 
at 4 weeks (Fig. 1). At least partial decrease (≥ 
2 pain scale decrease) was reported after 76% 
(16/21) and 68% (13/19) of treatments at one 
week and 4 weeks, respectively. Complete pain 
response (pain scale score ≤ 1) was reported 
after 24% (5/21) and 47% (9/19) of treatments 
at one week and one month, respectively. No 
significant change in pain (< 2 pain scale differ-
ence) was reported after 24% (4/21) and 32% 
(6/19) of treatments at one week and 4 weeks, 
respectively (Table 1). One patient could not be 
reached during the one week follow-up period. 
At 4 weeks, one patient was deceased and 2 
could not be reached.
Patient opioid use was decreased in 62% 
(13/21), remained unchanged in 19% (4/21), and 
increased in 19% (4/21) at 4 week follow-up. 
General activity level at 4 weeks after ablation 
treatments was increased in 81% (17/21) and 
decreased in 19% (4/21) (Fig. 2). One lesion (3%; 
1/36) was re-treated with RFA for recurrent pain 
and imaging evidence of recurrent tumor. 
Complications
According to Society of Interventional Ra-
diology guidelines, no major complication, such 
Fig. 1. Pain scale response following concurrent RT and ablation 
treatment.
Table 1. Categorical response to treatment after concurrent RT and 
ablation.
Pain Score Change from 
Baseline
Time from RT and Ablation
1 week 1 month
Complete 5 (24%) 9 (47%)
At least partial (≥2) 16 (76%) 13 (68%)
Nonresponder (<2) 5 (24%) 6 (32%)
Total responses 21 19
Fig. 2. Activity and pain medication use changes after concurrent RT and ablation.
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as permanent neural thermal injury, occurred as a result 
of spinal percutaneous ablation. There were post proce-
dural infections. One patient with a tumor involving the 
pedicle had new radicular pain after RFA (4.5%, 1/22) 
that resolved after transforaminal epidural. 
Post Treatment Imaging
Thirteen (13/22) of the ablation treatments had 
follow-up imaging at least 3 months later, consisting of 
CT, MRI, and/or PET/CT (median 6 months; range 2 – 27 
months). Five patients had between 3 and 6 months, 6 
patients had between 6 – 12 months, and 2 patients had 
more than 12 months of post ablation imaging. Nine of 
the patients had limited or no follow-up imaging, there-
fore were not included in the post-procedure imaging 
evaluation. Six patients had 1 – 6 weeks of follow-up 
imaging and 3 patients had no imaging follow-up. 
Post-procedural imaging (median 6 months; range 
2 – 27 months) showed stable treated disease in 12/13 
patients at 3 months and 10/10 at 6 months, despite 
systemic progression of disease. Two cases (2/13) with 
epidural extension had retraction of tumor from the 
epidural space. There was imaging evidence of tumor 
progression at the ablation margins in one patient at 
3 months. Another patient with less than 3 months of 
follow-up imaging had progressive vertebral collapse, 
increased retropulsion, and tumor progression at 4 
Fig. 3. A 62-year-old man with metastatic non-small cell lung carcinoma and painful pathologic compression fracture at T8. 
Sagittal T1FS post contrast image (A) one month prior to planned combined cEBRT and RFA show a pathologic fracture of  T8 
and diffuse enhancement of  the vertebral body. Sagittal T1FS post contrast images (B, C) 1.5 months after treatment showing 
tumor progression at the peripheral margins of  the ablation (C) and within the posterior elements (B) (arrows). The patient’s 
pre-procedural pain score (10/10) decreased to 3 at one week and 0 at 4 weeks. 
weeks after concurrent therapy. The remaining lesions 
were stable during the duration of imaging follow-up 
available (Figs. 3-6). 
discussion
Percutaneous ablation, either RFA or cyroablation, 
and RT have different mechanisms of alleviating pain 
and causing tumor death in spinal metastases that may 
work synergistically by compensating for the other’s 
shortcomings (15). Debilitating pain may be caused 
by spinal cord or nerve root compression from mass 
effect, pathologic fracture with mechanical instability, 
periosteal nociceptor stimulation from inflammation, 
tumor-derived products (e.g., tumor necrosis factor), 
or tumor-induced cytokines (24,25). RFA uses thermal 
energy to destroy tissue surrounding an electrode, re-
sulting in destruction of pain sensitive nerve fibers and 
decreased cytokine mediated pain from tumor necrosis 
(25,26). Cryoablation relies on Joule-Thomson effect 
of rapid freezing with argon gas and thawing with 
helium gas as they expand to achieve cell death and 
ischemia from microvascular thrombosis (27). Both RFA 
and cryoablation are effective in treating osseous meta-
static disease, but are dependent on the conduction of 
thermal energy which dissipates with distance from the 
probe tip, resulting in decreased efficacy around the 
tumor edge (11-15,28). Conversely, RT is dependent on 
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Fig. 4. A 66-year-old man with metastatic 
colon cancer and painful pathologic 
compression fracture of  L4 that failed to 
respond to cEBRT. Sagittal STIR (A) 
and T1FS post contrast image (B) 2 
days prior to RFA show the L4 pathologic 
fracture and metastases to the adjacent L3 
and L5 levels. Sagittal STIR (C) and 
T1FS post contrast images (D) 2 months 
after concurrent RT and RFA show 
tumor progression, further L4 vertebral 
body collapse and increased retropulsion 
(arrows). The patient had no response to 
combined therapy. 
Fig. 5. A 62-year-old man with metastatic desmoplastic melanoma with right L5 radicular pain. Pretreatment axial T1FS post-
contrast image at L5 (A) shows a large enhancing mass in the right aspect of  L5. Stereotactic CT shows the planned radiation 
isodose lines (B). SBRT and RFA (D) were performed concurrently. Post treatment axial T1FS post-contrast image at L5 (C) 
demonstrates the ablation zone (arrowhead) and cement (arrow) in the right aspect of  L5. Subsequent 6 month follow-up sagittal 
T2 image (F) shows stable treated disease at L5 compared to pretreatment sagittal T2 image (E), while there is new multilevel 
spinal disease and systemic progression (not shown) despite chemotherapy.
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oxygen for cytotoxicity and is thought to be 
deficient in killing centrally located tumor 
cells that are often hypoxic (29). This theory 
was investigated in a retrospective cohort 
study by DiStaso et al (15), who compared the 
pain responses of 15 patients with solitary 
axial and appendicular osseous metastases 
treated with RFA followed by cEBRT (20 Gy 
in 5 fractions) with 30 patients treated with 
cEBRT alone. The combination therapy group 
included 5 (33%; 5/15) vertebral and 2 (13%; 
2/15) sacral lesions, and the RT group includ-
ed 2 (6.6%; 2/30) vertebral and 8 (27%; 8/30) 
sacral lesions. At 12 week follow-up, patients 
in the combined treatment group more fre-
quently reported both complete [53% (8/15) 
vs 17% (5/30); P = 0.027] and at least partial 
[93% (14/15) vs 60% (18/30); P = 0.048] pain 
relief (15). However, only a small percentage 
of their treated lesions involved the spine and 
sacrum.
In this study, combined RFA and RT were 
effective at alleviating pain that was uncon-
trollable with conventional methods. The 
single case of combined RT and cryoablation 
had complete response. Cryoablation is typi-
cally used in osteoblastic metastases because 
the sclerotic bone lends to high impedance 
and prevents efficient radiofrequency tissue 
ablation. Some of the treated lesions were ra-
diation resistant tumors based on histology or 
prior radiation failure, defined as persistent 
or recurrent symptoms, or imaging evidence 
of tumor progression after RT. The majority 
of patients were able to reduce opioid use 
and increase their activity, which may lead 
to an improved quality of life. In terms of 
safety, one patient (4.5%; 1/22) experienced 
temporary radicular pain attributable to RFA. 
However, there were no permanent neuro-
logical injuries. Given these encouraging re-
sults, a randomized control trial is warranted 
to compare the efficacy of combined RT and 
percutaneous ablation with RT alone.
In addition to pain relief, concurrent 
therapy controlled tumors locally in a major-
ity of cases. Two patients with epidural ex-
tension of tumor had tumor retraction from 
the epidural space after treatment, which 
may have prevented or prolonged time to 
malignant spinal cord compression. These results are particularly 
intriguing given recent technical advances that permit ablation 
of metastases involving the posterior vertebral body and pedicles 
with navigational radiofrequency probes that permit real-time 
monitoring of the ablation volume (14,16,30). Additionally, the 
risk of radiation myelopathy often precludes adequate treat-
ment of tumor involving the posterior vertebral body, pedicles, 
neural foramina, and/or epidural space. Both ablation and SBRT 
of radiation resistant tumors alone have a higher likelihood of 
failure when the tumor involves the pedicles and neuroforamen 
(14,31). Randomized control trials are needed to assess whether 
combined therapy achieves superior local tumor control com-
pared with RT alone. 
There are several limitations of this retrospective study. The 
efficacy of combined RFA and RT for pain palliation cannot be 
isolated from that of vertebral augmentation, which was per-
Fig. 6. A 62-year-old man with lumbar rectal metastases. Sagittal (A) 
and axial (B) T2 images 6 weeks prior to treatment show pathologic 
compression fracture at L3 and L4 with retropulsion at L4 causing 
severe canal stenosis. Sagittal (C) and axial (D) T2 images 2 weeks 
after completion of  concurrent RT and RFA show tumor retraction from 
the canal at L4. Two months after treatment, CT (not shown) revealed 
mild osseous canal stenosis without soft tissue in the epidural space.
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The prescribed RT regimens in this study were 
variable including both conventional single and frac-
tionated RT, as well as SBRT, which may have different 
safety and efficacy profiles. There is ongoing debate 
regarding which RT regimen to employ (5). However, 
data are accumulating in support of SBRT for spinal me-
tastases in oligometastatic disease and radioresistant 
histology. Future prospective, multi-armed trials should 
randomize patients with pathologic stable fractures to 
RT and vertebral augmentation; RT, ablation, and ver-
tebral augmentation; and ablation plus augmentation 
in order to elucidate the most effective multimodality 
oftreatment in the palliative management of meta-
static spine disease.
conclusion
Combined radiation therapy and percutaneous 
ablation is safe and effective in palliating painful spinal 
metastases and controlling local tumor progression. 
This combined therapy is also effective in tradition-
ally resistant tumor histology. Future prospective multi-
armed studies should be designed to determine the 
palliative and local tumor control benefit of combined 
RT and percutaneous ablation, particularly for radia-
tion resistant tumors and metastases involving the pos-
terior vertebral body, pedicles, neural foramina, and/or 
epidural space that cannot be adequately treated with 
either modality alone.
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